For Second Act, Acorda Drops $525 Million On Inhaled Parkinson's Drug

September 24, 2014 1:01 PM

16 0

Chief Executive Ron Cohen, 58, an internist and former off-Broadway actor, has built Acorda, which he founded in 1995, into a profitable concern with $355 million in sales over the past four quarters, almost all of it from Ampyra, a pill that helps multiple sclerosis patients maintain their ability to walk.

Cohen, has also become a well-loved figure in biotech circles: well spoken, charming, and full of opinions on industry trends. His Twitter account? “Ron Cohen’s Hair,” after a series of jokes made by ISI analyst Mark Schoenebaum, a Cohen fan.

Read more

To category page